Time-restricted eating (TRE) is a form of intermittent fasting. Instead of focusing on how much you eat, TRE focuses on when you eat. A typical schedule might allow meals only between 12 PM and 8 PM ...

A 12-year study reveals how disrupted sleep may predict Huntington’s disease onset, could link to changes in thinking and ...

New research maps Huntington’s disease progression like a symphony unraveling. The brain first overcommunicates, then loses sync, and finally falls silent, each stage driven by different biological ...

This month, Huntington’s disease (HD) research offered powerful insights into how the brain changes over time, and how we might slow or track that progression. From using brain scans, smartphone tests ...

Pridopidine (previously called huntexil) is an experimental oral drug being developed primarily for Huntington’s disease (HD), and now also for ALS. It was originally thought to act by influencing ...

The Huntington’s disease mutation worsens over time like a dangerous snowball. By harnessing the power of the gene editing tool CRISPR, scientists may have found a way to interrupt the HD mutation and ...

Casgevy is the first CRISPR-based drug to make its way through the approval process, all but curing Sickle Cell Disease and it’s paving the way for similar drugs targeting other diseases. Is ...

As we wave goodbye to 2024, the HDBuzz team reflects on a year marked by significant progress, challenges, and hope. From breakthroughs at the lab bench, advancements in drug development, and both ...

The Huntington Study Group (HSG) is a clinical research network focused on accelerating treatments for Huntington’s disease (HD). This year, the annual conference is being held in Cincinnati, where ...

Researchers have updated the system that classifies Huntington’s disease progression. Tracking progression in 4 stages will make clinical trial screening and data interpretation easier and faster, and ...

Roche gave an update this week about GENERATION HD2, testing the HTT-lowering drug tominersen in people with HD. The trial is continuing, but only the higher dose will move forward. What does this ...

The HDBuzz editorial team had a virtual sit-down with HDBuzz founder, editor emeritus, Huntington’s disease (HD) researcher, and neurologist Professor Ed Wild. We laughed, we cried… actually we just ...